MYCN and neuroblastoma: The standard treatment for HR-NB relies on multimodal protocols, involving intensive chemotherapy, surgical resection, radiation therapy, and hematopoietic stem cell transplantation, alongside targeted therapies addressing MYCN amplification, anaplastic lymphoma kinase (ALK) mutations, and signaling pathway abnormalities (3, 4).